Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the fourth quarter and year ended December 31, 2012 on Wednesday, February 13, 2013, after the U.S. financial markets close.
